Litcius/Paper detail

Sultiame once per day in obstructive sleep apnoea (FLOW): a multicentre, randomised, double-blind, placebo-controlled, dose-finding, phase 2 trial

Winfried Randerath, Ludger Grote, Kaj Stenlöf, Ingo Fietze, Julia Chevts, Erik Buntinx, J. Bravo Albares, Katrin Kuhn, Corinna Hansen, Andreas Völp, Jan Hedner, Dries Testelmans, Jean‐Benoît Martinot, Farhad Baharloo, Benny Mwenge, Erik Buntinx, Pierre Philip, Jean‐Louis Pépin, Frédéric Gagnadoux, Maxime Patout, Marìa Fernanda Troncoso Acevedo, Maria Fernanda Troncoso Acevedo, F Martínez-Orozco, Francisco Javier Puertas, Ainhoa Álvarez Ruiz De Larrínaga, Francisco Javier Albares Tendero, Christian Viniol, Winfried Randerath, Heike Beneš, Ingo Fietze, Geert Mayer, Ingo Fietze, Geert Mayer, Peter Heymer, Frank Kaessner, Peter Heymer, Henning Candler, Zbyšek Pavelek, Samuel Genzor, Zbyšek Pavelek, Samuel Genzor

2025The Lancet9 citationsDOI

Topics & Concepts

MedicineSleep (system call)Internal medicineCardiologySleep apnea syndromesPhase (matter)AnesthesiaClinical trialSleep StagesPolysomnographySleep apneaMEDLINEObstructive Sleep Apnea ResearchSleep and Wakefulness ResearchNeuroscience of respiration and sleep
Sultiame once per day in obstructive sleep apnoea (FLOW): a multicentre, randomised, double-blind, placebo-controlled, dose-finding, phase 2 trial | Litcius